Cell Biotech Co., Ltd. (KOSDAQ: 049960)
South Korea
· Delayed Price · Currency is KRW 13,560
+10 (0.07%)
Nov 15, 2024, 9:00 AM KST
Cell Biotech Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 12,966 | 6,304 | 8,281 | 10,383 | 3,189 | 7,231 | Upgrade
|
| Depreciation & Amortization | 3,934 | 3,904 | 3,638 | 3,789 | 3,685 | 2,621 | Upgrade
|
| Loss (Gain) From Sale of Assets | 82.4 | 82.45 | 0.91 | -29.05 | -9.48 | -24.68 | Upgrade
|
| Loss (Gain) From Sale of Investments | 164.97 | 211.19 | - | -111.68 | 50.69 | - | Upgrade
|
| Provision & Write-off of Bad Debts | 0.58 | -0.1 | -0.39 | -0.44 | 1.83 | -7.03 | Upgrade
|
| Other Operating Activities | 1,425 | -215.9 | 154.35 | 441.37 | 3,279 | -2,888 | Upgrade
|
| Change in Accounts Receivable | 366.79 | 51.01 | 39.38 | 144.48 | 10.32 | 4,575 | Upgrade
|
| Change in Inventory | -60.03 | -19.33 | -506.84 | -79.79 | -379.03 | -1,847 | Upgrade
|
| Change in Accounts Payable | -558.54 | -875.33 | 96.3 | 271.08 | -217.78 | -144.83 | Upgrade
|
| Change in Unearned Revenue | -0.32 | -3.86 | -19.54 | 8.92 | 10.33 | -27.04 | Upgrade
|
| Change in Income Taxes | -643.39 | -643.39 | - | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | 631.47 | -979.12 | 1,131 | 74.98 | -55.21 | 742.8 | Upgrade
|
| Operating Cash Flow | 18,309 | 7,815 | 12,814 | 14,892 | 9,564 | 10,231 | Upgrade
|
| Operating Cash Flow Growth | 96.18% | -39.01% | -13.96% | 55.71% | -6.52% | -26.80% | Upgrade
|
| Capital Expenditures | -734.47 | -1,552 | -2,368 | -848.59 | -3,079 | -9,468 | Upgrade
|
| Sale of Property, Plant & Equipment | 69.15 | 0 | 1.7 | 16.77 | 11.05 | 760.72 | Upgrade
|
| Sale (Purchase) of Intangibles | -148.85 | -123.92 | -304.2 | 25.86 | -13.8 | -241.2 | Upgrade
|
| Investment in Securities | -7,255 | -3,062 | -4,138 | -10,499 | 1,511 | 4,306 | Upgrade
|
| Other Investing Activities | 7.57 | 12.17 | 38.62 | 2.6 | 112.42 | 129.76 | Upgrade
|
| Investing Cash Flow | -8,081 | -4,745 | -6,669 | -11,132 | -1,627 | -4,390 | Upgrade
|
| Long-Term Debt Repaid | - | -641.07 | -636.49 | -676.15 | -668.04 | -393.86 | Upgrade
|
| Total Debt Repaid | -645.11 | -641.07 | -636.49 | -676.15 | -668.04 | -393.86 | Upgrade
|
| Net Debt Issued (Repaid) | -645.11 | -641.07 | -636.49 | -676.15 | -668.04 | -393.86 | Upgrade
|
| Repurchase of Common Stock | - | - | -3,719 | - | -2,607 | -4,721 | Upgrade
|
| Dividends Paid | -3,080 | -3,080 | -3,182 | -3,182 | -4,341 | -4,502 | Upgrade
|
| Financing Cash Flow | -3,725 | -3,721 | -7,538 | -3,858 | -7,616 | -9,617 | Upgrade
|
| Foreign Exchange Rate Adjustments | -99.79 | 76.91 | -9.33 | 357.88 | -144.49 | -142.99 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | 0 | 0 | -0 | - | - | - | Upgrade
|
| Net Cash Flow | 6,404 | -573.48 | -1,402 | 260.35 | 177.19 | -3,920 | Upgrade
|
| Free Cash Flow | 17,575 | 6,264 | 10,445 | 14,044 | 6,485 | 763.21 | Upgrade
|
| Free Cash Flow Growth | 165.64% | -40.03% | -25.62% | 116.55% | 749.73% | -88.89% | Upgrade
|
| Free Cash Flow Margin | 32.49% | 11.65% | 20.67% | 29.96% | 14.23% | 1.66% | Upgrade
|
| Free Cash Flow Per Share | 2566.47 | 915.24 | 1515.03 | 1985.94 | 914.17 | 103.01 | Upgrade
|
| Cash Interest Paid | 74.18 | 61.95 | 37.49 | 42.48 | 39.08 | 8.8 | Upgrade
|
| Cash Income Tax Paid | 182.51 | 1,355 | 1,371 | -136.75 | -500.6 | 4,645 | Upgrade
|
| Levered Free Cash Flow | 8,573 | -335.57 | 5,547 | 9,207 | 3,057 | 2,721 | Upgrade
|
| Unlevered Free Cash Flow | 8,620 | -296.85 | 5,571 | 9,233 | 3,088 | 2,755 | Upgrade
|
| Change in Net Working Capital | -709.09 | 3,898 | -823.65 | -1,731 | -203.87 | -6,221 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.